These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 16869816)

  • 61. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction.
    Broderick GA; Brock GB; Roehrborn CG; Watts SD; Elion-Mboussa A; Viktrup L
    Urology; 2010 Jun; 75(6):1452-8. PubMed ID: 20163842
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function.
    Kunz C; Luedtke D; Unseld A; Hamilton A; Halabi A; Wein M; Formella S
    Int J Chron Obstruct Pulmon Dis; 2016; 11():585-95. PubMed ID: 27051282
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses.
    Brock GB; McMahon CG; Chen KK; Costigan T; Shen W; Watkins V; Anglin G; Whitaker S
    J Urol; 2002 Oct; 168(4 Pt 1):1332-6. PubMed ID: 12352386
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference.
    Ströberg P; Murphy A; Costigan T
    Clin Ther; 2003 Nov; 25(11):2724-37. PubMed ID: 14693300
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy.
    Kim ED; Seftel AD; Goldfischer ER; Ni X; Burns PR
    J Sex Med; 2014 Mar; 11(3):820-30. PubMed ID: 23841532
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Evaluation of tadalafil for the treatment of erectile dysfunction].
    Liu ZY; Sun YH
    Zhonghua Nan Ke Xue; 2008 Apr; 14(4):377-80. PubMed ID: 18481436
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Efficacy and safety of once-daily tadalafil in men with erectile dysfunction who reported no successful intercourse attempts at baseline.
    Shabsigh R; Seftel AD; Kim ED; Ni X; Burns PR
    J Sex Med; 2013 Mar; 10(3):844-56. PubMed ID: 23035781
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Treatment of male erectile dysfunction following spinal cord injuries using PDE5 inhibitors].
    Srámková T; Sutorý M
    Rozhl Chir; 2008 May; 87(5):250-4. PubMed ID: 18595542
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.
    Gupta M; Kovar A; Meibohm B
    J Clin Pharmacol; 2005 Sep; 45(9):987-1003. PubMed ID: 16100293
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.
    Egerdie RB; Auerbach S; Roehrborn CG; Costa P; Garza MS; Esler AL; Wong DG; Secrest RJ
    J Sex Med; 2012 Jan; 9(1):271-81. PubMed ID: 21981682
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function in men with erectile dysfunction but naive to phosphodiesterase type 5 inhibitors.
    Porst H; Brock GB; Kula K; Moncada I; Montorsi F; Basson BR; Kinchen K; Aversa A
    J Androl; 2012; 33(6):1305-22. PubMed ID: 22790642
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Testosterone:estradiol ratio changes associated with long-term tadalafil administration: a pilot study.
    Greco EA; Pili M; Bruzziches R; Corona G; Spera G; Aversa A
    J Sex Med; 2006 Jul; 3(4):716-722. PubMed ID: 16839328
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oliceridine.
    Nafziger AN; Arscott KA; Cochrane K; Skobieranda F; Burt DA; Fossler MJ
    Clin Pharmacol Drug Dev; 2020 Jul; 9(5):639-650. PubMed ID: 31697049
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction.
    Swan SK; Hursting MJ
    Pharmacotherapy; 2000 Mar; 20(3):318-29. PubMed ID: 10730687
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial.
    Young JM; Feldman RA; Auerbach SM; Kaufman JM; Garcia CS; Shen W; Murphy AM; Beasley CM; Hague JA; Ahuja S
    J Androl; 2005; 26(3):310-8. PubMed ID: 15866997
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence.
    Frajese GV; Pozzi F; Frajese G
    Clin Interv Aging; 2006; 1(4):439-49. PubMed ID: 18046921
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
    Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
    J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
    [TBL] [Abstract][Full Text] [Related]  

  • 78. No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers.
    Spence R; Mandagere A; Harrison B; Dufton C; Boinpally R
    J Pharm Sci; 2009 Dec; 98(12):4962-74. PubMed ID: 19455620
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US.
    Rajfer J; Aliotta PJ; Steidle CP; Fitch WP; Zhao Y; Yu A
    Int J Impot Res; 2007; 19(1):95-103. PubMed ID: 16871272
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effect of hepatic or renal impairment on eltrombopag pharmacokinetics.
    Bauman JW; Vincent CT; Peng B; Wire MB; Williams DD; Park JW
    J Clin Pharmacol; 2011 May; 51(5):739-50. PubMed ID: 20663991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.